Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxytocin nasal spray for social communication in male adolescents with autism spectrum disorders
ACTRN12609000513213Phase 3Completed
- Sponsor
- University of Sydney
- Start
- Feb 2009
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Autism Spectrum Disorder (ASD) comparing Syntocinon with Placebo nasal spray (2 arms). Primary endpoint: Social functioning. Started Feb 2009; status: completed.
02
Drugs
oxytocin
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on ACTRN12609000513213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12609000513213.